Greg from Mexico

Registered at the short selling broker eToro, 4 minutes ago.

» Try eToro you too
75% of retail investor accounts lose money when trading CFDs with etoro.
Don't show again

Rocket Pharmaceuticals, Inc. (RCKT) shares information

Rocket Pharmaceuticals, Inc.


24h Change

3.25 %

RCKT

Live rate: Market closed

Stock data per Wednesday 25 Nov, 2020

RCKT
NASDAQ
30.14
30.32
31.12
0.98 (+ 3.25%)
US Market is closed

Live Stock price in graph for Rocket Pharmaceuticals, Inc. (RCKT)

  • Latest Volume

    308,130 (-57.8 %)

  • Volume prev. day

    730,099

  • Avg. daily volume

    348,804

  • Market cap

    1,718,875,856

  • P/E ratio

    -17.12

  • Today high

    31.91 USD

  • Today low

    30 USD

  • 52 week high

    35 USD

  • 52 week low

    9.01 USD

  • YTD Change

    + 36.76 %

Quick links

Broker recommendations for Rocket Pharmaceuticals

The Rocket Pharmaceuticals, Inc. stock is rated at 1.041667 (on a scale 1-3, where 1 is ‘strong buy‘ and 3 is ‘strong sell‘) from Thursday 5 November, 2020 by a total of 12 brokers. This means that the consensus of the 12 different brokers is leaning toward to buy.

Sell
0 (0%)
Underweight
0 (0%)
Hold
0 (0%)
Overweight
1 (8.33%)
Buy
11 (91.67%)

Price target by analysts

The 10 latest analyst estimates, per Friday 20 November, 2020, show the following high, low and average price targets.
Target Average: 39.6 USD
Target High: 47 USD
Target Low: 34 USD

 

Latest news about Rocket Pharmaceuticals, Inc.

Below you can find the most recent news posts about Rocket Pharmaceuticals, Inc., primarily from US and UK based news sources.

Rocket Pharmaceuticals Receives Funding from the California Institute for Regenerative Medicine for Phase 1 Clinical Trial of RP-L401 for Infantile Malignant Osteopetrosis

Friday, 13 November 2020, 13:00:00
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies
— Business Wire


The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping

Thursday, 5 November 2020, 13:54:15
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 4) Abbott Laboratories (NYSE: ABT ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Anavex Life Sciences Corp (NASDAQ: AVXL ) Aptevo Therapeutics Inc (NASDAQ: APVO ) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) Ascendis Pharma A/S (NASDAQ: ASND ) Athira Pharma Inc (NASDAQ: ATHA ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO ) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ) BioLife Solutions Inc (NASDAQ: BLFS ) Cardiff Oncology Inc (NASDAQ: CRDF ) Denali Therapeutics Inc (NASDAQ: DNLI ) – moved in sympathy with Biogen Inc (NASDAQ: BIIB ) Guardant Health Inc (NASDAQ: GH ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Hologic, Inc. (NASDAQ: HOLX ) Idera Pharmaceuticals Inc (NASDAQ: IDRA ) Inspire Medical Systems Inc (NYSE: INSP ) Immunovant Inc (NASDAQ: IMVT ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) Kodiak Sciences Inc (NASDAQ: KOD ) Laboratory Corp.
— Benzinga


Rocket Pharmaceuticals to Present Data from its Fanconi Anemia, Leukocyte Adhesion Deficiency-I and Pyruvate Kinase Deficiency Programs at the 62nd American Society of Hematology Annual Meeting – Stocks News Feed

Wednesday, 4 November 2020, 16:37:00
Share this Stock InformationNEW YORK–(BUSINESS WIRE)–$RCKT #GeneTherapy—Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces presentations at the upcoming 62nd American Society of Hematology (ASH) Annual Meeting being held virtually December 5-8, 2020. There will be two oral presentations highlighting… Read More »Rocket Pharmaceuticals to Present Data from its Fanconi Anemia, Leukocyte Adhesion Deficiency-I and Pyruvate Kinase Deficiency Programs at the 62nd American Society of Hematology Annual Meeting
— Stocks News Feed


The Daily Biotech Pulse: Amarin Vascepa Data, Galapagos Osteoarthritis Drug Update, 4 IPOs

Friday, 16 October 2020, 13:15:07
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 15) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Beam Therapeutics Inc (NASDAQ: BEAM ) Bio-Rad Laboratories, Inc. Class B Common Stock (NYSE: BIO ) Kronos Bio Inc (NASDAQ: KRON ) (IPOed Friday) Larimar Therapeutics Inc (NASDAQ: LRMR ) Pacific Biosciences of California Inc (NASDAQ: PACB ) Rocket Pharmaceuticals Inc (NASDAQ: RCKT ) Twist Bioscience Corp (NASDAQ: TWST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Oct. 15) ADC Therapeutics SA (NYSE: ADCT ) Alector Inc (NASDAQ: ALEC ) Artelo Biosciences Inc (NASDAQ: ARTL ) Aziyo Biologics Inc (NASDAQ: AZYO ) Codiak BioSciences Inc (NASDAQ: CDAK ) (listed on Nasdaq Wednesday) Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX ) Dyne Therapeutics Inc (NASDAQ: DYN ) Pandion Therapeutics Inc (NASDAQ: PAND ) ProQR Therapeutics NV (NASDAQ: PRQR ) Silence Therapeutics ADR Representing 3 Ord Shs (NASDAQ: SLN ) Titan Pharmaceuticals, Inc. common stock (NASDAQ: TTNP ) (provided a strategic and corporate update) Uniqure NV (NASDAQ: QURE ) Stocks In Focus Zogenix Presents Data Showing Durability of Response For Seizure Drug Zogenix, Inc. (NASDAQ: ZGNX ) released interim data from open-label extension trial, showing substantial seizure reductions were maintained when treated with Fintepla oral solution for up to two years.
— Benzinga


The Daily Biotech Pulse: J&J Pauses Coronavirus Vaccine Studies, Voyager's Huntington's Disease Study Placed On Hold, Altimmune Vaccine Data

Tuesday, 13 October 2020, 14:20:13
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 12) 10X Genomics Inc (NASDAQ: TXG ) Acceleron Pharma Inc (NASDAQ: XLRN ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) argenx SE – ADR (NASDAQ: ARGX ) Beigene Ltd (NASDAQ: BGNE ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Blueprint Medicines Corp (NASDAQ: BPMC ) Calliditas Therapeutics Adr Rep 2 Ord Shs (NASDAQ: CALT ) Cardiff Oncology Inc (NASDAQ: CRDF ) CareDx Inc (NASDAQ: CDNA ) Castle Biosciences Inc (NASDAQ: CSTL ) Denali Therapeutics Inc (NASDAQ: DNLI ) Fate Therapeutics Inc (NASDAQ: FATE ) Immunovant Inc (NASDAQ: IMVT ) Insmed Incorporated (NASDAQ: INSM ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) Kronos Bio Inc (NASDAQ: KRON ) (went public Friday) Kura Oncology Inc (NASDAQ: KURA ) Kymera Therapeutics Inc (NASDAQ: KYMR ) Lantern Pharma Inc.
— Benzinga


Trading broker recommendation

We recommend that you check out Capital.com as they have a very good selection of stocks available for both going short and long.

Rating: 9.57/10
Minimum deposit: €200
Description: Capital.com offer a large number of stocks for trading. Register an account today and check if they have RCKT available or trade one of the many other CFD stocks they have.
Risk warning: 75% of retail investor accounts lose money when trading CFDs with Capital.